Surgery Partners (SGRY) Stock Could Be 19% Undervalued As Growth And Debt Concerns Build

Recent commentary on Surgery Partners (SGRY) has focused on slowing sales volume growth, softer revenue growth expectations, and ongoing high debt levels. This combination appears to be affecting sentiment toward the stock.

See our latest analysis for Surgery Partners.

At a share price of $14.55, Surgery Partners has seen a 30 day share price return of 7.86% and a 90 day share price return of 23.31%. However, the 1 year total shareholder return is down 24.61%, pointing to some recent momentum after a much weaker longer term experience.

If you are reassessing healthcare exposure after Surgery Partners' recent moves, it could be a good time to scan for other opportunities through 41 healthcare AI stocks.

With Surgery Partners trading at $14.55 and screens suggesting a large intrinsic discount plus room to the average analyst target, the key question is simple: is this pricing in too much risk, or is the market already assuming healthier future growth?

Most Popular Narrative: 19% Undervalued

With Surgery Partners at $14.55 against a widely followed fair value estimate of about $17.95, the current setup centers on whether margin repair and future earnings catch up to that valuation.

The accelerated migration of high-acuity surgical procedures (particularly orthopedics and joint replacements) from hospitals to outpatient settings is strengthening, with Surgery Partners demonstrating outperformance through investments in robotics and facility capabilities, positioning the company to capitalize on expanding case volumes and higher-revenue procedures directly supporting long-term revenue and EBITDA growth.

Read the complete narrative.

Want to see what is baked into that fair value for Surgery Partners? The narrative leans on rising revenues, improving margins, and a richer earnings profile. The precise mix of growth, profitability, and valuation multiples may surprise you.

Result: Fair Value of $17.95 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that fair value narrative for Surgery Partners is vulnerable if anesthesia cost pressures persist, or if slower acquisitions and portfolio changes drag on margins and cash generation.

Find out about the key risks to this Surgery Partners narrative.

Next Steps

Seeing both upside and risk in the Surgery Partners story so far? Take a closer look at the numbers now and shape your own stance with the 3 key rewards.

Looking for more investment ideas beyond Surgery Partners?

If Surgery Partners has you rethinking your portfolio, do not stop here. Use the Simply Wall Street Screener to uncover fresh, data driven ideas across sectors.

• Target potential mispricings by scanning for companies that appear attractively valued using the 45 high quality undervalued stocks.
• Strengthen your defense by focusing on companies with resilient finances through the 66 resilient stocks with low risk scores.
• Get ahead of the crowd by hunting for lesser known quality opportunities using the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com